Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00522873 · ClinicalTrials.gov registry record · Phase 3

Endometrial Safety Study

A Phase 3 study of Postmenopause, sponsored by Bayer.

Completed
Registry status
Phase 3
Development phase
662
Enrollment target
20
Study locations

NCT00522873 is a Phase 3 study of Postmenopause that has completed, run by Bayer. The registered enrollment target is 662 participants, above the 126-participant average among 5 other Postmenopause trials with a reported enrollment target (425% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00522873, a Phase 3 study of Postmenopause, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 3
Development phase
662 participants
Enrollment target
20
Study locations

Study Summary

The study is designed to investigate the safety of the investigational product for the lining of the uterus (endometrium).

Conditions Studied

Interventions

  • DRUG 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
  • DRUG 0.5mg NETA / 1.0mg E2 (Activella)

Study Locations (20)

California

  • - San Diego
  • - San Diego

Colorado

  • - Denver
  • - Greenwood Village

Florida

  • - Boynton Beach
  • - Clearwater

Louisiana

  • - Amite
  • - Marrero

Buenos Aires

  • - Lanús Oeste
  • - San Isidro

Arizona

  • - Chandler

Idaho

  • - Boise

Nevada

  • - Las Vegas

Trial Details

FieldValue
Enrollment Target 662 participants
Start Date 2007-08
Est. Completion 2009-08
Phase Phase 3

Sponsor

Bayer

591 total trials

What the Registry Record Tells You About NCT00522873

The ClinicalTrials.gov registry entry for NCT00522873 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 662 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 126-participant average among 5 other Postmenopause trials with a reported enrollment target (425% higher). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Postmenopause appearing as the primary indexed condition, and to 2 interventions - of which 0.25mg DRSP / 0.5mg E2 (BAY86-4891) is the first listed.

NCT00522873 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT00522873 about?

NCT00522873 is a clinical study titled "Endometrial Safety Study". The study is designed to investigate the safety of the investigational product for the lining of the uterus (endometrium).

What is the current status of trial NCT00522873?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 662 participants. The study started on 2007-08. Estimated completion is 2009-08.

What conditions does trial NCT00522873 study?

This clinical trial studies the following conditions: Postmenopause.

What interventions are being tested in trial NCT00522873?

The interventions under investigation include: 0.25mg DRSP / 0.5mg E2 (BAY86-4891) (DRUG), 0.5mg NETA / 1.0mg E2 (Activella) (DRUG).

Who is sponsoring clinical trial NCT00522873?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00522873 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postmenopause

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.